Search Results

FILTER BY

1 - 10 of 10 matches

Sort by:

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

June 5, 2023

NewsConference NewsAHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

NewsConference NewsACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

NewsConference NewsISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 4, 2018

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

NewsConference NewsACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

NewsConference NewsACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 5, 2018

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Advertisement

Advertisement

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.